A prognostic model for HIV seroconversion among injection drug users as a tool for stratification in clinical trials

被引:20
作者
Boileau, C
Bruneau, J
Al-Nachawati, H
Lamothe, F
Vincelette, J
机构
[1] Univ Montreal, Ctr Hosp, Dept Social & Prevent Med, Montreal, PQ, Canada
[2] Univ Montreal, Ctr Hosp, Res Ctr, Montreal, PQ, Canada
[3] Univ Montreal, Dept Family Med, Montreal, PQ, Canada
[4] Univ Montreal, Dept Immunol & Microbiol, Montreal, PQ, Canada
关键词
prognostic model; risk score; survival study; HIV behavioral risk factors; injection drug use;
D O I
10.1097/01.qai.0000153424.56379.61
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: The main goal of this study was to construct a prognostic model for HIV seroconversion among injection drug users (IDUs) using easy-to-measure risk indicators. Design: Cox proportional hazards regression modeling was used for risk stratification in a heterogeneous population of IDUs with regards to HIV risk-taking behaviors. Methods: Subjects were recruited in a prospective cohort of IDUs followed between September 1992 and October 2001. A total of 1602 men, seronegative at enrollment with at least 1 follow-up visit, were included in the analyses. Only variables that consistently predict HIV seroconversion in several settings were considered. The final model was used to assign a risk score for each participant. Results: Three risk indicators were included in the risk score to predict HIV seroconversion: unstable housing, average cocaine injections per day, and having shared a syringe with a known HIV-positive partner. Kaplan-Meier survival functions were generated and risk score values stratified in 3 groups. HIV incidence rates per 100 person-years were as follows: 0.91 (95% Cl, 0.55-1.52) for the low-risk group, 3.10 (95% Cl, 2.49-3.84) for the moderate-risk group, and 7.82 (95% Cl, 6.30-9.73) for the high-risk group (log-rank P value < 0.0001). Conclusion: If validated in other settings, this risk score may improve the prediction of outcome and allow more accurate stratification in clinical trials.
引用
收藏
页码:489 / 495
页数:7
相关论文
共 48 条
[1]  
ALARY M, 2000, CAN J INFECT DIS SB, V11
[2]   INJECTION-DRUG USE AND HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
ALCABES, P ;
FRIEDLAND, G .
CLINICAL INFECTIOUS DISEASES, 1995, 20 (06) :1467-1479
[3]   NEW EVIDENCE ON INTRAVENOUS COCAINE USE AND THE RISK OF INFECTION WITH HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 [J].
ANTHONY, JC ;
VLAHOV, D ;
NELSON, KE ;
COHN, S ;
ASTEMBORSKI, J ;
SOLOMON, L .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1991, 134 (10) :1175-1189
[4]  
Bruneau J, 1997, AM J EPIDEMIOL, V146, P994, DOI 10.1093/oxfordjournals.aje.a009240
[5]  
Bruneau J, 2001, CAN MED ASSOC J, V164, P767
[6]   A probability-based approach for predicting HIV infection in a low prevalent population of injection drug users [J].
Cheng, FK ;
Ford, WL ;
Weber, MD ;
Cheng, SY ;
Kerndt, PR .
ANNALS OF EPIDEMIOLOGY, 1997, 7 (01) :28-34
[7]   RISK-FACTORS FOR HIV-1 SEROCONVERSION AMONG INJECTION-DRUG USERS - A CASE-CONTROL STUDY [J].
CHITWOOD, DD ;
GRIFFIN, DK ;
COMERFORD, M ;
PAGE, JB ;
TRAPIDO, EJ ;
LAI, SG ;
MCCOY, CB .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1995, 85 (11) :1538-1542
[8]  
*COM PERM LUTT TOX, 2000, POINT SIT TOX QUEB A
[9]  
COX DR, 1972, J R STAT SOC B, V34, P187
[10]  
DeIrala J, 1996, AM J EPIDEMIOL, V143, P725, DOI 10.1093/oxfordjournals.aje.a008806